Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were up 5.1% during trading on Tuesday . The company traded as high as $128.13 and last traded at $127.70. Approximately 1,344,696 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 1,761,062 shares. The stock had previously closed at $121.49.

Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Barclays boosted their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research report on Friday, September 28th. Stifel Nicolaus lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the company from $154.00 to $130.00 in a research report on Tuesday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Finally, ValuEngine lowered shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $160.74.

The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72. The firm has a market cap of $30.98 billion, a price-to-earnings ratio of 23.98, a P/E/G ratio of 1.27 and a beta of 0.79.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.58. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $976.81 million. During the same quarter in the previous year, the firm earned $1.56 earnings per share. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts predict that Alexion Pharmaceuticals, Inc. will post 6.45 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the business. First Hawaiian Bank purchased a new position in Alexion Pharmaceuticals during the third quarter valued at approximately $102,000. Point72 Asia Hong Kong Ltd lifted its holdings in Alexion Pharmaceuticals by 3,156.7% during the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 947 shares in the last quarter. Advisory Services Network LLC lifted its holdings in Alexion Pharmaceuticals by 145.3% during the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 523 shares in the last quarter. Berson & Corrado Investment Advisors LLC purchased a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $205,000. Finally, Financial Gravity Wealth Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $211,000. 93.06% of the stock is currently owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: Can individual investors take part in an IPO?

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.